Israeli Study Supports 3rd Dose (Booster) of Pfizer COVID-19 Vaccine

The patient is wise to look away. If you watch the needle go in, it’ll hurt more.

The study at hand compared thousands of folks in Israel who got the booster dose with those who didn’t. Everybody got the original Pfizer 2-shot vaccine at least six months previously. The study period included some months when the delta variant was dominant (about seven weeks starting in August 2021). Median follow-up of study participants was a surprisingly low 13 days.

Nevertheless, the booster seemed to reduce hospitalization, severe disease, and death from COVID-19.

See The Lancet for details.

Steve Novella has more details at Science-Based Medicine.

Steve Parker, M.D.

Comments are closed.